Roche Holding stock heads toward the October 22 sales update

Published on 10/07/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock was last at CHF 345.70 on October 2, 2026, after a 0.95 percent session decline. Giredestrant delivered 10.0 months of median PFS versus 5.5 months.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding stock (ISIN CH1499059983) was last at CHF 345.70 on the SIX Swiss Exchange on October 2, 2026, down 0.95 percent from CHF 349.00. The next company checkpoint is Roche's third-quarter sales update on October 22, 2026, according to Roche.

October 22 brings the next update

The scheduled sales release gives investors the next quantified read on demand across Roche's Pharmaceuticals and Diagnostics divisions. The October 22 event is listed by Roche as a virtual presentation at 2:00 p.m. CEST, making the date a defined checkpoint for the pipeline narrative and group sales trend.

Roche's investor page reports core earnings per share of CHF 19.46 for fiscal year 2025, with growth of 11 percent at constant exchange rates. The same page says 39 million patients received Roche medicines in 2025, while 31 billion diagnostic tests were delivered to customers worldwide.

Giredestrant adds a clinical catalyst

The strongest recent company event is the October 1, 2026, publication of phase III evERA data. According to Roche, giredestrant plus everolimus produced median progression-free survival of 10.0 months in the ESR1-mutated population, versus 5.5 months for the comparator.

The same results showed median progression-free survival of 8.8 months versus 5.5 months in the intent-to-treat population. Roche also stated that the combination reduced the risk of progression or death by 62 percent in the ESR1-mutated group and by 44 percent across the intent-to-treat population.

The regulatory calendar now gives the data a second checkpoint: the FDA goal date is November 30, 2026, for early-stage disease and December 18, 2026, for advanced disease. The dates are company targets, not approval decisions, so the clinical result and the regulatory timetable represent separate milestones.

Consensus leaves room for debate

MarketScreener lists a Hold consensus from five analysts, with an average target of CHF 375.34, a high of CHF 434.50 and a low of CHF 230.00. The average target lies 8.57 percent above the CHF 345.70 share price, based on the figures published by MarketScreener.

One named analyst action points in the same direction. MarketScreener reported on September 8, 2026, that Barclays retained a Buy rating and raised its target from CHF 410 to CHF 430.

Roche shares remain above the yearly start

At CHF 345.70 on October 2, 2026, the stock was 0.95 percent below the previous session and 6.34 percent higher year to date. The same SIX quote showed a session high of CHF 349.90, a low of CHF 342.50 and volume of 611,234 shares.

For investors, the October 22 sales update will test whether the pipeline progress is translating into broader commercial momentum. The giredestrant data improve the clinical case, while the Hold consensus and wide CHF 230.00 to CHF 434.50 target spread show that valuation remains contested.